N V Khachanova, K Z Bakhtiyarova, A N Boyko, Y V Vlasov, M V Davydovskaya, E P Evdoshenko, M N Zakharova, S V Kotov, E V Popova, S A Sivertseva, N A Totolyan, F A Khabirov
Alemtuzumab (Lemtrada) is a recombinant humanized IgG1 kappa monoclonal antibody to the surface cell glycoprotein, a CD52 differentiation cluster. The drug is approved for use in more than 65 countries, including the Russian Federation. The drug is one of the most effective methods of treating patients with aggressive multiple sclerosis, but the risk management plan should be followed. The safety profile of the drug includes infusion-associated reactions, thyroid dysfunction, immune cytopenia, acute cardiovascular events, infections, and other autoimmune diseases...
2020: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova